When George Reed was diagnosed with stage four prostate cancer he was given ‘months to live’. He sought a second opinion from Prof Lisa Horvath, Director of Medical Oncology and Research.
“She told me, ‘You’re only early stage four. I think I can give you some more time.’ Just those words meant everything to me. They meant hope.”
George was administered a chemotherapy drug called Docetaxel, which is the subject of a collaborative study led by Prof Horvath and medical oncologist Dr Kate Mahon.
The research has confirmed that a blood marker, mGTSP1, can predict outcomes after Docetaxel in men with metastatic castrate resistant prostate cancer.
This research may accelerate future clinical trials of new therapies and be useful in the clinic to guide treatment decisions. The academic paper reporting these findings was the subject of an editorial in the journal European Urology.
George said he experiences fatigue and pain as side-effects of the treatment. “But I am incredibly thankful for the precious extra time I have been given to spend with my wife and family.”